MC
TRDA icon

Merck & Co’s Entrada Therapeutics TRDA Stock Holding History

Merck & Co’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8M Hold
1,739,768
– – 2.43% 6
2026
Q1 		$22M Hold
1,739,768
– – 6.28% 4
2025
Q4 		$17.9M Hold
1,739,768
– – 6.47% 4
2025
Q3 		$10.1M Hold
1,739,768
– – 4.43% 5
2025
Q2 		$11.7M Hold
1,739,768
– – 5.42% 4
2025
Q1 		$15.7M Hold
1,739,768
– – 9.57% 4
2024
Q4 		$30.1M Buy
+1,739,768
New +$31.5M 11.66% 4

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Merck & Co's TRDA Position: Q2 2026 in Review

Merck & Co held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 1,739,768 shares worth $12.8M. The position accounts for 2.43% of the portfolio, ranked #6.

Merck & Co first reported a position in TRDA in Q4 2024 and has held it in 7 quarters since. The position peaked at $30.1M in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Merck & Co held 1,739,768 shares of Entrada Therapeutics worth $12.8M as of Q2 2026.
  • Merck & Co left its Entrada Therapeutics share count unchanged in Q2 2026.
  • Entrada Therapeutics made up 2.43% of Merck & Co's portfolio in Q2 2026, its #6 holding.
  • Merck & Co first reported a position in Entrada Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Merck & Co's Entrada Therapeutics position peaked at $30.1M in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Merck & Co's 13F filing for Q2 2026, filed 7 Aug 2026.